REG - AstraZeneca PLC - AstraZeneca plans to invest $50bn in the US

AstraZenecaAnnouncement

22/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250722:nRSV9506Ra&default-theme=true

RNS Number : 9506R  AstraZeneca PLC  22 July 2025

22 July 2025

AstraZeneca plans to invest $50 billion in America for medicines manufacturing
and R&D

Investment will support AstraZeneca's ambition to reach $80 billion revenue by
2030, with 50% generated in the US

Cornerstone of investment is a proposed new multi-billion dollar drug
substance manufacturing centre focused on chronic diseases in the Commonwealth
of Virginia, the Company's largest single investment in a facility to date

 

AstraZeneca today announces $50 billion of investment in the United States by
2030, building on America's global leadership in medicines manufacturing and
R&D. This investment is expected to create tens of thousands of new,
highly skilled direct and indirect jobs across the country powering growth and
delivering next generation medicines for patients in America and worldwide.

 

The cornerstone of this landmark investment is a new multi-billion dollar US
manufacturing facility that will produce drug substances for the Company's
innovative weight management and metabolic portfolio, including oral GLP-1,
baxdrostat, oral PCSK9 and combination small molecule products. The new
state-of-the-art centre will produce small molecules, peptides and
oligonucleotides. This multi-billion dollar capital investment is in addition
to the $3.5 billion announced in November 2024.

 

The drug substance facility, planned to be in the Commonwealth of Virginia,
would be AstraZeneca's largest single manufacturing investment in the world.
The facility will leverage AI, automation, and data analytics to optimise
production.

 

The $50 billion investment across our R&D and manufacturing footprint in
the US over the next five years also includes:

 

·    Expansion of our R&D facility in Gaithersburg, Maryland

·    State-of-the-art R&D centre in Kendall Square, Cambridge,
Massachusetts

·    Next-generation manufacturing facilities for cell therapy in
Rockville, Maryland and Tarzana, California

·    Continuous manufacturing expansion in Mount Vernon, Indiana

·    Specialty manufacturing expansion in Coppell, Texas

·    New sites to supply clinical trials

·    Our growing research and development investment in novel medicines

 

Collectively, these investments will help deliver AstraZeneca's ambition of
reaching $80 billion in Total Revenue by 2030, of which we expect 50% would be
generated in the US.

 

Howard Lutnick, US Secretary of Commerce, said: "For decades Americans have
been reliant on foreign supply of key pharmaceutical products. President Trump
and our nation's new tariff policies are focused on ending this structural
weakness. We are proud that AstraZeneca has made the decision to bring
substantial pharmaceutical production to our shores.  This historic
investment is bringing tens of thousands of jobs to the US and will ensure
medicine sold in our country is produced right here."

 

Governor Glenn Youngkin, Commonwealth of Virginia, said: "I want to thank
AstraZeneca for choosing Virginia as the cornerstone for this transformational
investment in the United States. This project will set the standard for the
latest technological advancements in pharmaceutical manufacturing, creating
hundreds of highly skilled jobs and helping further strengthen the nation's
domestic supply chain. Advanced manufacturing is at the heart of Virginia's
dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading
pharmaceutical companies, plans to make their largest global manufacturing
investment here in the Commonwealth."

 

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today's
announcement underpins our belief in America's innovation in
biopharmaceuticals and our commitment to the millions of patients who need our
medicines in America and globally. It will also support our ambition to reach
$80 billion in revenue by 2030. I look forward to partnering with Governor
Youngkin and his team to work on our largest single manufacturing investment
ever. It reflects the Commonwealth of Virginia's desire to create highly
skilled jobs in science and technology, and will strengthen the country's
domestic supply chain for medicines."

 

Notes

 

AstraZeneca in the US

The US is AstraZeneca's largest market and home to 19 R&D, manufacturing
and commercial sites.  We employ more than 18,000 people and support 92,000
jobs overall across the United States. In 2024 we contributed $5 billion
directly to the economy and created approximately $20 billion worth of overall
value for the American economy.

 

Today the US represents 42% of our Total Revenue with an ambition to reach 50%
by 2030. This underscores the critical role the US plays in our ability to
deliver on our ambition to launch 20 new medicines by the end of the decade.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)
.

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUQAMUPAGRG